BCM
CCCC icon

Bronte Capital Management’s C4 Therapeutics CCCC Stock Holding History

Bronte Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.3K Buy
10,349
+316
+3% +$1.08K 0.01% 45
2026
Q1 		$26.4K Hold
10,033
– – ﹤0.01% 49
2025
Q4 		$19.2K Buy
+10,033
New +$23.8K ﹤0.01% 44

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bronte Capital Management's CCCC Position: Q2 2026 in Review

Bronte Capital Management increased its C4 Therapeutics (CCCC) stake by 3.1% in Q2 2026, buying an estimated $1.08K and bringing the position to 10,349 shares worth $48.3K. The position accounts for 0.01% of the portfolio, ranked #45.

Bronte Capital Management first reported a position in CCCC in Q4 2025 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Bronte Capital Management held 10,349 shares of C4 Therapeutics worth $48.3K as of Q2 2026.
  • Bronte Capital Management bought 316 C4 Therapeutics shares in Q2 2026, an estimated $1.08K.
  • C4 Therapeutics made up 0.01% of Bronte Capital Management's portfolio in Q2 2026, its #45 holding.
  • Bronte Capital Management first reported a position in C4 Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Bronte Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.